Skip to main content

Table 1 Clinical data

From: Gene-guided Gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive Non-small cell lung cancer: an economic analysis

Parameter

Values

Description and references

Weibull survival model of PFS in the Control strategy

Scale = 0.1559;

[11]

Shape = 1.045;

r2 = 0.976

Weibull survival model of OS for supportive care

Scale = 0.04006;

 

Shape = 1.156;

[20]

r2 = 0.9898

Weibull survival model of OS for 2nd-line chemotherapy

Scale = 0.03897;

[20]

Shape = 1.509;

r2 = 0.981

HR of PFS for the Gefitinib strategy in patients with an EGFR mutation

0.17 (95% CI:0.07–0.42)

[11]

Frequency of EGFR mutations

50% (range: 8%–70%)*

[11]

Proportion of patients receiving 2nd-line chemotherapy

56.6% (range: 26%–72%)*

[5–10]

Frequency of follow-up

 0–2 years

Once per four months

[26]

 after 2 years

Once per year

[26]

Probability of SAEs in the Gefitinib strategy

7% (range: 5.25%–8.75%)*

[11]

Probability of SAEs in the Control strategy

3% (range: 2.25%–3.75%)*

[11]

Probability of SAEs using platinum-based chemotherapy

80% (range: 60%–100%)*

[27]

  1. * The range was assumed for one-way sensitivity analysis.